Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cytomegalovirus | 42 | 2020 | 76 | 5.100 |
Why?
|
Cytomegalovirus Infections | 28 | 2020 | 79 | 4.140 |
Why?
|
DNA, Viral | 21 | 2020 | 96 | 1.670 |
Why?
|
Antiviral Agents | 18 | 2020 | 132 | 1.220 |
Why?
|
HIV Infections | 12 | 2020 | 980 | 1.180 |
Why?
|
HIV-1 | 6 | 2015 | 440 | 1.060 |
Why?
|
Viral Load | 10 | 2018 | 199 | 1.040 |
Why?
|
Ganciclovir | 14 | 2014 | 26 | 0.790 |
Why?
|
Antibodies, Viral | 7 | 2018 | 87 | 0.680 |
Why?
|
Drug Resistance, Viral | 7 | 2014 | 37 | 0.670 |
Why?
|
Viral Proteins | 9 | 2011 | 24 | 0.640 |
Why?
|
Cervix Uteri | 5 | 2015 | 38 | 0.610 |
Why?
|
Coinfection | 1 | 2015 | 29 | 0.530 |
Why?
|
Immunoglobulin G | 5 | 2018 | 129 | 0.530 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 5 | 2010 | 14 | 0.460 |
Why?
|
Humans | 57 | 2020 | 29361 | 0.450 |
Why?
|
Viremia | 4 | 2015 | 36 | 0.420 |
Why?
|
Antigens, CD | 4 | 2015 | 99 | 0.410 |
Why?
|
Alzheimer Disease | 2 | 2013 | 1943 | 0.410 |
Why?
|
Hepatitis B virus | 1 | 2011 | 7 | 0.410 |
Why?
|
Hepatitis B | 1 | 2011 | 19 | 0.400 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2011 | 47 | 0.400 |
Why?
|
Genome, Viral | 3 | 2010 | 12 | 0.390 |
Why?
|
Polymerase Chain Reaction | 5 | 2011 | 161 | 0.390 |
Why?
|
DNA-Directed DNA Polymerase | 8 | 2010 | 9 | 0.370 |
Why?
|
Lung Transplantation | 4 | 2014 | 18 | 0.350 |
Why?
|
Receptors, Cell Surface | 3 | 2015 | 50 | 0.340 |
Why?
|
Reagent Kits, Diagnostic | 2 | 2007 | 19 | 0.320 |
Why?
|
Indicators and Reagents | 1 | 2007 | 14 | 0.300 |
Why?
|
Female | 23 | 2020 | 16211 | 0.300 |
Why?
|
Membrane Glycoproteins | 4 | 2005 | 101 | 0.290 |
Why?
|
Virology | 1 | 2006 | 14 | 0.280 |
Why?
|
Viral Envelope Proteins | 4 | 2020 | 21 | 0.280 |
Why?
|
Molecular Sequence Data | 8 | 2006 | 246 | 0.280 |
Why?
|
Drug Resistance, Microbial | 9 | 2002 | 96 | 0.280 |
Why?
|
Chemokines, CXC | 1 | 2006 | 5 | 0.280 |
Why?
|
Reproducibility of Results | 6 | 2011 | 788 | 0.280 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 2 | 2015 | 16 | 0.280 |
Why?
|
Lipopolysaccharide Receptors | 2 | 2015 | 27 | 0.270 |
Why?
|
Interferon-gamma | 3 | 2015 | 109 | 0.270 |
Why?
|
T-Lymphocytes | 4 | 2013 | 212 | 0.270 |
Why?
|
Hepacivirus | 1 | 2006 | 73 | 0.270 |
Why?
|
Genital Diseases, Female | 1 | 2004 | 10 | 0.250 |
Why?
|
Base Sequence | 7 | 2009 | 135 | 0.250 |
Why?
|
Microbial Sensitivity Tests | 7 | 2016 | 111 | 0.240 |
Why?
|
Foscarnet | 8 | 2010 | 8 | 0.230 |
Why?
|
Amino Acid Sequence | 6 | 2006 | 193 | 0.230 |
Why?
|
Virus Replication | 7 | 2020 | 92 | 0.220 |
Why?
|
Herpesvirus 4, Human | 2 | 2020 | 13 | 0.220 |
Why?
|
RNA, Viral | 5 | 2016 | 149 | 0.220 |
Why?
|
Leukocytes | 2 | 2015 | 43 | 0.210 |
Why?
|
Fibroblasts | 5 | 2013 | 95 | 0.210 |
Why?
|
Interleukin-6 | 2 | 2015 | 108 | 0.210 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 553 | 0.200 |
Why?
|
Carotid Artery Diseases | 2 | 2012 | 44 | 0.200 |
Why?
|
Genotype | 5 | 2006 | 405 | 0.200 |
Why?
|
Mutation | 6 | 2009 | 383 | 0.190 |
Why?
|
Adult | 12 | 2020 | 8604 | 0.190 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 18 | 0.190 |
Why?
|
DNA Virus Infections | 1 | 2020 | 5 | 0.190 |
Why?
|
RNA Virus Infections | 1 | 2020 | 5 | 0.190 |
Why?
|
RNA Viruses | 1 | 2020 | 5 | 0.190 |
Why?
|
Salicylates | 1 | 2020 | 7 | 0.190 |
Why?
|
DNA Viruses | 1 | 2020 | 6 | 0.190 |
Why?
|
Male | 16 | 2020 | 15637 | 0.180 |
Why?
|
Isoxazoles | 3 | 2010 | 16 | 0.180 |
Why?
|
Viral Fusion Proteins | 1 | 2020 | 16 | 0.180 |
Why?
|
Lymphocyte Activation | 3 | 2013 | 209 | 0.180 |
Why?
|
Receptors, Immunologic | 2 | 2013 | 34 | 0.180 |
Why?
|
Hepatitis C | 2 | 2013 | 65 | 0.170 |
Why?
|
Genes, Viral | 3 | 2016 | 8 | 0.170 |
Why?
|
Neurocognitive Disorders | 1 | 2018 | 19 | 0.160 |
Why?
|
Anti-HIV Agents | 2 | 2018 | 171 | 0.160 |
Why?
|
Inflammation | 3 | 2015 | 345 | 0.160 |
Why?
|
Cytosine | 2 | 2010 | 6 | 0.160 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2011 | 46 | 0.160 |
Why?
|
Strophanthins | 1 | 2016 | 1 | 0.150 |
Why?
|
Methionine | 1 | 2016 | 3 | 0.150 |
Why?
|
Carotid Arteries | 3 | 2012 | 54 | 0.150 |
Why?
|
Open Reading Frames | 3 | 2006 | 12 | 0.150 |
Why?
|
Receptors, Tumor Necrosis Factor, Member 14 | 3 | 2013 | 3 | 0.150 |
Why?
|
Middle Aged | 10 | 2020 | 9823 | 0.150 |
Why?
|
Cells, Cultured | 7 | 2015 | 676 | 0.140 |
Why?
|
Biomarkers | 2 | 2018 | 692 | 0.140 |
Why?
|
Raltegravir Potassium | 1 | 2015 | 9 | 0.140 |
Why?
|
Tissue Donors | 1 | 1996 | 74 | 0.140 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 145 | 0.140 |
Why?
|
Sulfates | 1 | 2015 | 16 | 0.140 |
Why?
|
Organometallic Compounds | 1 | 2015 | 13 | 0.140 |
Why?
|
Interleukin-17 | 1 | 2015 | 27 | 0.140 |
Why?
|
Disease Transmission, Infectious | 1 | 2015 | 21 | 0.130 |
Why?
|
Interleukins | 1 | 2015 | 37 | 0.130 |
Why?
|
Indoles | 1 | 2015 | 48 | 0.130 |
Why?
|
Anti-Infective Agents, Local | 1 | 2015 | 52 | 0.130 |
Why?
|
Sequence Homology, Amino Acid | 5 | 1999 | 45 | 0.130 |
Why?
|
Cell Line | 5 | 2016 | 299 | 0.120 |
Why?
|
Organ Culture Techniques | 3 | 2011 | 31 | 0.120 |
Why?
|
Point Mutation | 1 | 1994 | 30 | 0.120 |
Why?
|
Viral Structural Proteins | 1 | 1992 | 4 | 0.110 |
Why?
|
Organophosphonates | 2 | 2010 | 5 | 0.110 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1992 | 19 | 0.110 |
Why?
|
Phylogeny | 3 | 2005 | 63 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2005 | 33 | 0.110 |
Why?
|
T-Lymphocyte Subsets | 1 | 2013 | 86 | 0.110 |
Why?
|
Killer Cells, Natural | 1 | 2013 | 91 | 0.110 |
Why?
|
Neurofibrillary Tangles | 1 | 2013 | 181 | 0.110 |
Why?
|
Decidua | 1 | 2011 | 1 | 0.100 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2011 | 19 | 0.100 |
Why?
|
Tumor Necrosis Factor-alpha | 3 | 2013 | 215 | 0.100 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 132 | 0.100 |
Why?
|
Sequence Homology, Nucleic Acid | 3 | 1999 | 16 | 0.100 |
Why?
|
Plasma | 1 | 2011 | 34 | 0.100 |
Why?
|
Vascular Stiffness | 1 | 2011 | 9 | 0.100 |
Why?
|
Amyloid beta-Peptides | 1 | 2013 | 294 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2020 | 140 | 0.100 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 18 | 0.100 |
Why?
|
Green Fluorescent Proteins | 2 | 2008 | 34 | 0.100 |
Why?
|
Genes, Reporter | 2 | 2008 | 30 | 0.100 |
Why?
|
Lymphocyte Subsets | 1 | 2011 | 30 | 0.100 |
Why?
|
Interleukin-8 | 2 | 2007 | 32 | 0.100 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 73 | 0.090 |
Why?
|
Toll-Like Receptors | 2 | 2007 | 28 | 0.090 |
Why?
|
Gene Expression | 4 | 2011 | 226 | 0.090 |
Why?
|
Anti-Infective Agents | 1 | 2009 | 63 | 0.090 |
Why?
|
Genetic Variation | 1 | 2009 | 105 | 0.080 |
Why?
|
Artemisinins | 1 | 2008 | 1 | 0.080 |
Why?
|
Skin | 2 | 2003 | 117 | 0.080 |
Why?
|
Betaherpesvirinae | 1 | 2008 | 1 | 0.080 |
Why?
|
Virion | 2 | 2020 | 13 | 0.080 |
Why?
|
Lymphoid Tissue | 1 | 2008 | 19 | 0.080 |
Why?
|
Foreskin | 1 | 2007 | 1 | 0.080 |
Why?
|
Poly I-C | 1 | 2007 | 6 | 0.080 |
Why?
|
Interferon-beta | 1 | 2007 | 7 | 0.080 |
Why?
|
Receptors, Virus | 2 | 2005 | 7 | 0.080 |
Why?
|
Cohort Studies | 3 | 2018 | 1939 | 0.080 |
Why?
|
Chemokine CXCL1 | 1 | 2007 | 3 | 0.080 |
Why?
|
HIV Core Protein p24 | 1 | 2007 | 29 | 0.080 |
Why?
|
Organ Transplantation | 2 | 2010 | 35 | 0.080 |
Why?
|
Culture Media | 1 | 2007 | 38 | 0.080 |
Why?
|
Stromal Cells | 1 | 2007 | 35 | 0.080 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 127 | 0.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 91 | 0.070 |
Why?
|
HEK293 Cells | 2 | 2020 | 70 | 0.070 |
Why?
|
Endothelial Cells | 1 | 2007 | 64 | 0.070 |
Why?
|
Nucleic Acid Hybridization | 1 | 1986 | 11 | 0.070 |
Why?
|
Laboratories | 1 | 2006 | 25 | 0.070 |
Why?
|
Genomic Instability | 1 | 2006 | 7 | 0.070 |
Why?
|
Glycosylation | 1 | 2006 | 24 | 0.070 |
Why?
|
Herpesviridae | 1 | 2005 | 2 | 0.070 |
Why?
|
Vaginosis, Bacterial | 1 | 2005 | 30 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 153 | 0.060 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2004 | 1 | 0.060 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2004 | 1 | 0.060 |
Why?
|
Therapeutic Irrigation | 1 | 2004 | 66 | 0.060 |
Why?
|
Saliva | 1 | 2004 | 53 | 0.060 |
Why?
|
Vagina | 1 | 2004 | 46 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 1992 | 130 | 0.060 |
Why?
|
Gene Amplification | 1 | 2003 | 19 | 0.060 |
Why?
|
Aged, 80 and over | 1 | 2013 | 4851 | 0.060 |
Why?
|
Cytomegalovirus Retinitis | 1 | 2003 | 4 | 0.060 |
Why?
|
Opportunistic Infections | 1 | 2002 | 8 | 0.060 |
Why?
|
Aged | 2 | 2014 | 9447 | 0.060 |
Why?
|
Phosphorylation | 2 | 2013 | 159 | 0.060 |
Why?
|
Flow Cytometry | 3 | 2015 | 199 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2020 | 638 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2001 | 26 | 0.050 |
Why?
|
Models, Biological | 2 | 2015 | 344 | 0.050 |
Why?
|
CD57 Antigens | 2 | 2011 | 5 | 0.050 |
Why?
|
ADP-ribosyl Cyclase 1 | 2 | 2011 | 18 | 0.050 |
Why?
|
HLA-DR Antigens | 2 | 2011 | 26 | 0.050 |
Why?
|
CD28 Antigens | 2 | 2011 | 16 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2016 | 323 | 0.050 |
Why?
|
Animals | 3 | 2020 | 4577 | 0.050 |
Why?
|
Vero Cells | 1 | 2020 | 7 | 0.050 |
Why?
|
DNA Replication | 1 | 2020 | 12 | 0.050 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2013 | 2 | 0.050 |
Why?
|
Virus Internalization | 1 | 2020 | 17 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2020 | 97 | 0.050 |
Why?
|
Risk Factors | 3 | 2014 | 2446 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2015 | 437 | 0.040 |
Why?
|
Astrocytes | 1 | 2020 | 122 | 0.040 |
Why?
|
Mental Status and Dementia Tests | 1 | 2018 | 80 | 0.040 |
Why?
|
Mucous Membrane | 2 | 2009 | 40 | 0.040 |
Why?
|
Signal Transduction | 2 | 2013 | 483 | 0.040 |
Why?
|
Cardiac Glycosides | 1 | 2016 | 1 | 0.040 |
Why?
|
Genes, Immediate-Early | 1 | 2016 | 2 | 0.040 |
Why?
|
Biological Transport, Active | 1 | 2016 | 16 | 0.040 |
Why?
|
Molecular Structure | 1 | 2016 | 28 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2016 | 44 | 0.040 |
Why?
|
Restriction Mapping | 1 | 1996 | 5 | 0.040 |
Why?
|
Sequence Alignment | 1 | 1996 | 22 | 0.040 |
Why?
|
DNA Primers | 1 | 1996 | 52 | 0.040 |
Why?
|
Models, Molecular | 1 | 2016 | 81 | 0.040 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 1992 | 36 | 0.030 |
Why?
|
Complement Inactivator Proteins | 1 | 1995 | 1 | 0.030 |
Why?
|
CD55 Antigens | 1 | 1995 | 2 | 0.030 |
Why?
|
CD59 Antigens | 1 | 1995 | 3 | 0.030 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 1995 | 12 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2002 | 957 | 0.030 |
Why?
|
Immunization | 1 | 2015 | 47 | 0.030 |
Why?
|
Administration, Intravaginal | 1 | 2015 | 1 | 0.030 |
Why?
|
Cell Lineage | 1 | 2015 | 29 | 0.030 |
Why?
|
Age Factors | 1 | 2018 | 845 | 0.030 |
Why?
|
Cell Separation | 1 | 2015 | 42 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2015 | 81 | 0.030 |
Why?
|
Cell Survival | 1 | 2015 | 169 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 264 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2015 | 146 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2018 | 965 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2015 | 90 | 0.030 |
Why?
|
Conserved Sequence | 1 | 1994 | 7 | 0.030 |
Why?
|
Risk Assessment | 2 | 2010 | 678 | 0.030 |
Why?
|
Simplexvirus | 2 | 1999 | 9 | 0.030 |
Why?
|
CD56 Antigen | 1 | 2013 | 8 | 0.030 |
Why?
|
Lymphotoxin-alpha | 1 | 2013 | 6 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 17 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 22 | 0.030 |
Why?
|
GPI-Linked Proteins | 1 | 2013 | 25 | 0.030 |
Why?
|
Interferon Type I | 1 | 2013 | 18 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2013 | 66 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2015 | 3476 | 0.030 |
Why?
|
Enzyme Activation | 1 | 2013 | 109 | 0.030 |
Why?
|
Demography | 1 | 2013 | 77 | 0.030 |
Why?
|
Cloning, Molecular | 1 | 1992 | 32 | 0.030 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 1992 | 7 | 0.030 |
Why?
|
Plasmids | 1 | 1992 | 44 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2013 | 56 | 0.030 |
Why?
|
Transfection | 1 | 1992 | 125 | 0.030 |
Why?
|
HIV Seropositivity | 1 | 2013 | 95 | 0.030 |
Why?
|
Antigens, Viral | 3 | 1998 | 19 | 0.030 |
Why?
|
Tunica Intima | 1 | 2012 | 26 | 0.030 |
Why?
|
Time Factors | 2 | 2011 | 1618 | 0.030 |
Why?
|
Phenotype | 2 | 2003 | 357 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2011 | 27 | 0.030 |
Why?
|
Cellular Senescence | 1 | 2011 | 19 | 0.020 |
Why?
|
Fetal Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
Off-Label Use | 1 | 2010 | 7 | 0.020 |
Why?
|
Models, Statistical | 1 | 2011 | 132 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2010 | 38 | 0.020 |
Why?
|
Prevalence | 1 | 2012 | 491 | 0.020 |
Why?
|
Pregnancy | 1 | 2011 | 404 | 0.020 |
Why?
|
Palatine Tonsil | 1 | 2009 | 7 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 170 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 220 | 0.020 |
Why?
|
Rectum | 1 | 2009 | 61 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 2009 | 213 | 0.020 |
Why?
|
Ultrasonography | 1 | 2011 | 226 | 0.020 |
Why?
|
Endothelium, Vascular | 2 | 1999 | 61 | 0.020 |
Why?
|
Young Adult | 1 | 2014 | 1935 | 0.020 |
Why?
|
Virus Shedding | 1 | 2007 | 13 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2010 | 3273 | 0.020 |
Why?
|
Ligands | 1 | 2007 | 55 | 0.020 |
Why?
|
Lymphocytes | 1 | 2008 | 110 | 0.020 |
Why?
|
Deoxyribonuclease BamHI | 1 | 1986 | 1 | 0.020 |
Why?
|
DNA Restriction Enzymes | 1 | 1986 | 4 | 0.020 |
Why?
|
Herpesvirus 1, Human | 1 | 2005 | 2 | 0.020 |
Why?
|
Binding, Competitive | 1 | 2005 | 29 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 1812 | 0.020 |
Why?
|
Binding Sites | 1 | 2005 | 71 | 0.020 |
Why?
|
Immunity, Mucosal | 1 | 2005 | 29 | 0.020 |
Why?
|
Toll-Like Receptor 2 | 1 | 2005 | 32 | 0.020 |
Why?
|
Toll-Like Receptor 4 | 1 | 2005 | 33 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 2004 | 11 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2004 | 8 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2004 | 15 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2004 | 59 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 265 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2004 | 56 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2005 | 173 | 0.020 |
Why?
|
Child | 1 | 2008 | 1345 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 90 | 0.010 |
Why?
|
Transplantation Immunology | 1 | 2002 | 2 | 0.010 |
Why?
|
Probability | 1 | 2002 | 94 | 0.010 |
Why?
|
Infant | 1 | 2004 | 531 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 138 | 0.010 |
Why?
|
Viral Plaque Assay | 2 | 1992 | 2 | 0.010 |
Why?
|
Graft Survival | 1 | 2002 | 98 | 0.010 |
Why?
|
Graft Rejection | 1 | 2002 | 76 | 0.010 |
Why?
|
Reference Values | 1 | 2002 | 227 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2002 | 241 | 0.010 |
Why?
|
Survival Rate | 1 | 2002 | 349 | 0.010 |
Why?
|
Umbilical Veins | 1 | 1999 | 3 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1999 | 28 | 0.010 |
Why?
|
Codon | 1 | 1999 | 7 | 0.010 |
Why?
|
Virulence | 1 | 1999 | 15 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1999 | 108 | 0.010 |
Why?
|
Uridine | 1 | 1999 | 2 | 0.010 |
Why?
|
Drug Resistance, Multiple | 1 | 1999 | 12 | 0.010 |
Why?
|
Immediate-Early Proteins | 1 | 1998 | 6 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2002 | 1829 | 0.010 |
Why?
|
Rats | 1 | 1999 | 858 | 0.010 |
Why?
|
Phosphonoacetic Acid | 1 | 1992 | 1 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1991 | 30 | 0.010 |
Why?
|